Jane Street’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.69M | Sell |
30,700
-55,200
| -64% | -$2.99M | ﹤0.01% | 5406 |
|
|
2025
Q4 | $4.21M | Sell |
85,900
-54,700
| -39% | -$2.55M | ﹤0.01% | 3504 |
|
|
2025
Q3 | $6.07M | Buy |
140,600
+60,800
| +76% | +$2.37M | ﹤0.01% | 3133 |
|
|
2025
Q2 | $3.06M | Buy |
79,800
+62,200
| +353% | +$2.38M | ﹤0.01% | 3714 |
|
|
2025
Q1 | $682K | Buy |
+17,600
| New | +$644K | ﹤0.01% | 6293 |
|
|
2024
Q4 | – | Sell |
-10,000
| Closed | -$409K | – | 9862 |
|
|
2024
Q3 | $409K | Buy |
+10,000
| New | +$409K | ﹤0.01% | 7532 |
|
|
2023
Q2 | – | Sell |
-7,700
| Closed | -$271K | – | 9024 |
|
|
2023
Q1 | $271K | Buy |
+7,700
| New | +$269K | ﹤0.01% | 7357 |
|
|
2022
Q4 | – | Sell |
-10,020
| Closed | -$292K | – | 9494 |
|
|
2022
Q3 | $292K | Buy |
10,020
+6,260
| +166% | +$237K | ﹤0.01% | 7635 |
|
|
2022
Q2 | $205K | Sell |
3,760
-6,960
| -65% | -$384K | ﹤0.01% | 8156 |
|
|
2022
Q1 | $584K | Sell |
10,720
-64,000
| -86% | -$3.48M | ﹤0.01% | 7177 |
|
|
2021
Q4 | $4.12M | Sell |
74,720
-42,800
| -36% | -$2.23M | ﹤0.01% | 3161 |
|
|
2021
Q3 | $5.61M | Sell |
117,520
-110,000
| -48% | -$5.53M | ﹤0.01% | 2556 |
|
|
2021
Q2 | $11.3M | Buy |
227,520
+156,960
| +222% | +$7.54M | ﹤0.01% | 1584 |
|
|
2021
Q1 | $3.15M | Sell |
70,560
-14,240
| -17% | -$646K | ﹤0.01% | 3159 |
|
|
2020
Q4 | $3.9M | Buy |
84,800
+42,880
| +102% | +$1.97M | ﹤0.01% | 2447 |
|
|
2020
Q3 | $1.97M | Buy |
41,920
+5,040
| +14% | +$253K | ﹤0.01% | 3059 |
|
|
2020
Q2 | $1.88M | Sell |
36,880
-11,600
| -24% | -$595K | ﹤0.01% | 3152 |
|
|
2020
Q1 | $2.3M | Buy |
+48,480
| New | +$2.59M | ﹤0.01% | 1882 |
|
|
2019
Q2 | – | Sell |
-7,280
| Closed | -$380K | – | 5362 |
|
|
2019
Q1 | $380K | Sell |
7,280
-20,640
| -74% | -$1.03M | ﹤0.01% | 3996 |
|
|
2018
Q4 | $1.33M | Buy |
+27,920
| New | +$1.37M | ﹤0.01% | 2189 |
|
|
2018
Q3 | – | Sell |
-6,560
| Closed | -$331K | – | 5332 |
|
|
2018
Q2 | $331K | Sell |
6,560
-6,720
| -51% | -$338K | ﹤0.01% | 4022 |
|
|
2018
Q1 | $649K | Buy |
+13,280
| New | +$618K | ﹤0.01% | 3168 |
|
|
2017
Q1 | – | Sell |
-6,960
| Closed | -$335K | – | 4351 |
|
|
2016
Q4 | $335K | Buy |
6,960
+480
| +7% | +$23.7K | ﹤0.01% | 3248 |
|
|
2016
Q3 | $349K | Sell |
6,480
-19,440
| -75% | -$1.07M | ﹤0.01% | 3141 |
|
|
2016
Q2 | $1.4M | Buy |
25,920
+10,240
| +65% | +$539K | 0.01% | 1621 |
|
|
2016
Q1 | $795K | Buy |
+15,680
| New | +$781K | ﹤0.01% | 2082 |
|
|
2015
Q4 | – | Sell |
-6,080
| Closed | -$292K | – | 4169 |
|
|
2015
Q3 | $292K | Buy |
6,080
+1,920
| +46% | +$99.9K | ﹤0.01% | 2822 |
|
|
2015
Q2 | $217K | Sell |
4,160
-1,760
| -30% | -$99.1K | ﹤0.01% | 3184 |
|
|
2015
Q1 | $342K | Buy |
+5,920
| New | +$339K | ﹤0.01% | 2406 |
|
|
2013
Q4 | – | Sell |
-20,240
| Closed | -$1.27M | – | 2562 |
|
|
2013
Q3 | $1.27M | Sell |
20,240
-68,720
| -77% | -$4.42M | 0.02% | 894 |
|
|
2013
Q2 | $5.56M | Buy |
+88,960
| New | +$5.65M | 0.1% | 155 |
|
Other funds holding GSK
JEST
Jane Street's GSK Position: Q1 2026 in Review
Jane Street reduced its GSK (GSK) stake by 38% in Q1 2026, selling an estimated $22.3M and leaving 661,399 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1272.
Jane Street first reported a position in GSK in Q2 2013 and has held it in 45 quarters since. The position peaked at $107M in Q3 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Jane Street held 661,399 shares of GSK worth $36.5M as of Q1 2026.
- Jane Street sold 411,956 GSK shares in Q1 2026, an estimated $22.3M.
- GSK made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1272 holding.
- Jane Street first reported a position in GSK in Q2 2013 and has held it in 45 quarters since.
- Jane Street's GSK position peaked at $107M in Q3 2019.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.